A Cuproptosis–Glycolysis Signature Predicts Prognosis and Highlights AURKA as a Therapeutic Target in ccRCC
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/6111105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 09.05.2026. Verfasst von Chang-Yu Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: Cuproptosis, Aurora Kinase A, Carcinoma, Renal Cell, Glycolysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cuproptosis, a recently identified form of cell death, is closely linked to glycolysis; however, the mechanistic interplay between these processes in clear cell renal cell carcinoma (ccRCC) remains to be fully elucidated. Utilizing data from the TCGA and CPTAC databases, we developed and validated a cuproptosis‐glycolysis–related gene (CuG) scoring model to investigate its associations with clinical outcomes, tumor immune infiltration, immunotherapy response, and drug sensitivity. Our analysis established a robust 10‐gene risk model with significant prognostic value that effectively stratifies ccRCC patients into distinct high‐ and low‐risk groups exhibiting marked differences in clinical profiles and therapeutic responses. Through integrated bioinformatic analyses alongside in vitro and in vivo experimental validation, we identified AURKA as a key functional regulator within this signature. Beyond promoting tumor cell proliferation, migration, and invasion, AURKA may have a significant role in modulating antitumor immunity. Collectively, by establishing a clinically applicable prognostic scoring system and nominating AURKA as a potential therapeutic target, our study offers translational implications for treatment decision‐making in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, cams.ac.cn.
- Department of Urology, China-Japan Friendship Hospital, Beijing, China, zryhyy.com.cn.
- China-Japan Friendship Clinical College, Peking University Health Science Center, Beijing, China, bjmu.edu.cn.
ORCID-Profile: Peng Liu, Jian-Feng Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, C. Y., Zhang, M. X., Tan, H. T., Sun, C. H., Sun, S. Z., Liu, P., & Wang, J. F. (2026). A Cuproptosis–Glycolysis Signature Predicts Prognosis and Highlights AURKA as a Therapeutic Target in ccRCC. Human Mutation, 2026(1). https://doi.org/10.1155/humu/6111105
Vancouver
Ma CY, Zhang MX, Tan HT, Sun CH, Sun SZ, Liu P, et al. A Cuproptosis–Glycolysis Signature Predicts Prognosis and Highlights AURKA as a Therapeutic Target in ccRCC. Human Mutation. 2026;2026(1). doi:10.1155/humu/6111105
BibTeX
@article{Ma2026,
author = {Ma, Chang-Yu and Zhang, Ming-Xiao and Tan, Hao-Tian and Sun, Chong-Hao and Sun, Shu-Zhan and Liu, Peng and Wang, Jian-Feng},
title = {A Cuproptosis–Glycolysis Signature Predicts Prognosis and Highlights AURKA as a Therapeutic Target in ccRCC},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/6111105}
}
EUVIMED